QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

MDGL

QT70Madrigal Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
505.75
+5.89+1.18%
OverviewShort InterestFilings
MDGLQT70Madrigal Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
505.75+1.18%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-12.80
Insider Own14.97%
Shs Outstand23.06M
Perf Week6.64%
Market Cap11.52BForward P/E48.24EPS next Y10.49Insider Trans0.16%Shs Float-Perf Month-1.19%
Enterprise Value11.64BPEG-EPS next Q-2.49Inst Own-Short Float-Perf Quarter11.34%
Income-245474016.00P/S10.18EPS this Y48.59%Inst Trans-Short Ratio-Perf Half Y-8.80%
Sales1.13BP/B26.70EPS next Y259.35%ROA-25.21%Short Interest-Perf YTD-13.15%
Book/sh23.55P/C-EPS next 5Y-ROE-50.15%52W High614.97 -17.76%Perf Year80.88%
Cash/sh35.47P/FCF-EPS past 3/5Y-ROIC-35.20%52W Low275.00 83.91%Perf 3Y-
Dividend Est.-EV/EBITDA-41.41Sales past 3/5Y-Gross Margin93.07%Volatility2.67% 2.59%Perf 5Y-
Dividend TTM-EV/Sales10.28EPS Y/Y TTM41.55%Oper. Margin-27.68%ATR (14)20.36Perf 10Y-
Dividend Ex-Date-Quick Ratio3.16Sales Y/Y TTM528.89%Profit Margin-27.32%RSI (14)53.43Recom2.09
Dividend Gr. 3/5Y-Current Ratio3.50EPS Q/Q2.11%SMA202.43%Beta0.53Target Price710.22
Payout0.00%Debt/Eq0.64Sales Q/Q127.01%SMA50-0.79%Rel Volume1.73Prev Close499.86
Employees528LT Debt/Eq0.59EarningsAug 04SMA2002.51%Avg Volume281.42KPrice505.75
IPO DateFeb 06, 2007Option/ShortYes / YesEPS/Sales Surpr.9.97% 3.32%Net Debt/EBITDA-0.41Volume486,971Change1.18%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-11-26ReiteratedMorgan Stanley$542
May-13-26ReiteratedTruist Financial$640 → $709
May-07-26ReiteratedEvercore ISI$652 → $649
May-07-26ReiteratedCanaccord GenuityBuy$420 → $578
Jan-27-26InitiatedBarclaysOverweight$964
Jan-14-26ReiteratedGoldman SachsBuy$375 → $571
Jan-06-26ReiteratedWolfe Research$579
Dec-19-25ReiteratedUBSBuy$540 → $900
Dec-19-25ReiteratedPiper SandlerOverweight$540 → $900
Nov-21-25ReiteratedH.C. WainwrightBuy$568 → $620
Latest News
Jun-11-26
Jun-11-2608:10AM
B of A Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $542Benzinga
08:10AM
B of A Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $542Benzinga
Jun-10-26
Jun-10-2606:04PM
Viking Therapeutics: Drugs Are In The Pipeline, But Profitability Is Still UnprovenSeekingAlpha
02:22PM
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,132958180
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A78566
Gross Profit1,054902174
Selling, General and Administrative Excl. Other915814435
Research and Development453389237
Other Operating Expense-1-10
Operating Income-314-300-498
Interest Expense262215
Unusual Expense
———
Non-Operating Income (Expense)-30-34-47
Net Income Before Taxes-309-288-466
Income Taxes
000
Consolidated Net Income-309-288-466
Net Income From Continuing Operations-309-288-466
Net Income-309-288-466
EPS (Recurring)-12.80-12.85-21.90
EPS (Basic, Before Extraordinaries)-12.80-12.85-21.90
EPS (Diluted)-12.80-12.85-21.90
EBITDA-281-264-450
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio12.9613.37—
Gross Margin93.1194.1596.67
Operating Margin-27.74-31.32-276.67
Net Margin-27.30-30.06-258.89
Shares Outstanding292221
Market Capitalization14,66712,811—
Operating Lease Expense
———
Insider Trading Volume
$534.62$478.57$422.51$366.46$310.41● Close Price0.00M22.04M44.07M66.11M88.14MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Soergel DavidChief Medical OfficerJun 01 '26Sale495.741,042516,56110,033Jun 01 12:00 AM
Levy Richard SDirectorMay 22 '26Sale515.445,6822,928,71622,015May 22 12:00 AM
Soergel DavidChief Medical OfficerMay 18 '26Sale515.90844435,42011,075May 18 12:00 AM
Dier MardiEVP and CFOMar 06 '26Sale430.871,982853,99112,490Mar 06 12:00 AM
Sibold William JohnPresident and CEOMar 06 '26Sale431.941,663718,316161,829Mar 06 12:00 AM
Kelley Shannon TGeneral CounselMar 06 '26Sale431.94360155,49812,138Mar 06 12:00 AM
Huntsman CaroleChief Commercial OfficerMar 06 '26Sale431.94419180,98312,692Mar 06 12:00 AM
Taub RebeccaDirectorMar 06 '26Sale431.94491212,083452,213Mar 06 12:00 AM
Dier MardiEVP and CFOMar 02 '26Sale427.211,183505,3899,257Mar 02 12:00 AM
Levy Richard SDirectorFeb 23 '26Option Exercise7.365,00036,80027,697Feb 24 12:00 AM
Taub RebeccaDirectorJan 26 '26Sale492.42647318,596452,704Jan 26 12:00 AM
Levy Richard SDirectorJan 26 '26Option Exercise16.468,000131,68025,197Jan 26 12:00 AM
Huntsman CaroleChief Commercial OfficerJan 26 '26Sale493.78910449,3399,122Jan 26 12:00 AM
Sibold William JohnPresident and CEOJan 26 '26Sale492.421,577776,546148,497Jan 26 12:00 AM
Kelley Shannon TGeneral CounselJan 20 '26Sale497.36692344,1748,481Jan 20 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR